|
| 产品描述 |
| Motolimod, also known as VTX-2337, is a small-molecule Toll-like receptor 8 (TLR8) agonist with potential immunostimulating and antineoplastic activities. TLR8 agonist VTX-2337 binds to TLR8, present in cutaneous dendritic cells, monocytes/macrophages, and mast cells, which may result in the activation of the central transcription factor nuclear factor-B, the secretion of proinflammatory cytokines and other mediators, and a Th1-weighted antitumoral cellular immune response. Primarily localized to endosomal membranes intracellularly, TLR8, like other TLRs, recognizes pathogen-associated molecular patterns (PAMPs) and plays a key role in the innate immune system. |
| 化学结构 |
 |
| 化学名称 |
| 2-amino-N,N-dipropyl-8-(4-(pyrrolidine-1-carbonyl)phenyl)-3H-benzo[b]azepine-4-carboxamide |
| SMILES Code |
| O=C(C1=CC2=CC=C(C3=CC=C(C(N4CCCC4)=O)C=C3)C=C2N=C(N)C1)N(CCC)CCC |
| 基本信息 |
产品编号:XM065
产品名称:Motolimod (VTX-2337)
CAS#:926927-61-9
分子式:C28H34N4O2
精确分子量:458.26
分子量:458.6
纯度:>98%
|
| 物化性质 |
外观: 固体粉末状
纯度: >98%
运输信息: 非危险化学品，适于常温或冰袋运输。
储存条件: 低温，干燥，避光。
溶解性: 溶于DMSO, 不溶于水
储存期限: 3 年 -20℃ 固体储存 2 年 -80℃ 溶液储存 |
该产品只供科研使用，不能给病人提供。
|
|
|
